This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Rifampicin

Authoring team

Rifampicin is a drug that is indicated in:

  • tuberculosis
  • meningococcal meningitis prophylaxis
  • leprosy

Cautious use is required:

  • it discolours soft contact lenses
  • reduce dose in:
    • hepatic impairment
    • alcoholism
    • pregnancy
  • users of the oral contraceptive pill should take additional contraceptive precautions

Contra-indications to its use are:

  • jaundice
  • porphyria

Side-effects of rifampicin include:

  • shortness of breath
  • collapse and shock
  • acute renal failure
  • thrombocytopenic purpura
  • gastrointestinal symptoms
  • influenzal syndrome
  • hepatic reactions with alterations of liver function, jaundice, urticaria and rashes
  • urine, saliva and other secretions coloured orange-red

Routes of administration:

  • oral:
    • tablets
    • capsules
    • syrup
  • i.v. infusion

The summary of product characteristics should be consulted before prescribing this drug.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.